MMP inhibition and the development of cerebrovascular atherosclerosis: The road ahead.
Napoli
Claudio
C
D000818:Animals; D001921:Brain / Q000098:blood supply / Q000201:enzymology*; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005109:Extracellular Matrix / Q000201:enzymology; D005260:Female; D005998:Glycine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D020244:Infarction, Middle Cerebral Artery / Q000201:enzymology; D002537:Intracranial Arteriosclerosis / Q000188:drug therapy* / Q000201:enzymology* / Q000517:prevention & control; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000235:genetics / Q000378:metabolism; D020778:Matrix Metalloproteinase 2 / Q000235:genetics / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000378:metabolism; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000235:genetics / Q000378:metabolism; D051379:Mice; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D016896:Treatment Outcome
D004791:Enzyme Inhibitors; D006877:Hydroxamic Acids; C107086:KB R7785; D061965:Matrix Metalloproteinase Inhibitors; D013876:Thiophenes; D010649:Phenylalanine; C080985:batimastat; D020782:Matrix Metalloproteinases; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D020781:Matrix Metalloproteinase 1; D005998:Glycine